Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardio Diagnostics HoldingsCDIO +0.15%49 Quick Ratio is 15.77 as of Mar. 2026, which is 75% above its 10-year median of 9.00. GuruFocus rates CDIO with a GF Score™ of 49/100 and a GF Value™ of $2.77 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Cardio Diagnostics Holdings ranks better than 88.02% on this metric.
Cardio Diagnostics Holdings has a quick ratio of 15.77. It generally indicates good short-term financial strength.
The historical rank and industry rank for Cardio Diagnostics Holdings's Quick Ratio or its related term are showing as below:
CDIO'
s Quick Ratio Range Over the Past 10 Years
Min: 0.64 Med: 9 Max: 23.65
Current: 15.77
During the past 6 years, Cardio Diagnostics Holdings's highest Quick Ratio was 23.65. The lowest was 0.64. And the median was 9.00.
CDIO's Quick Ratio is ranked better than 88.02% of 1411
companies
in the Biotechnology industry
Industry Median: 3.57
vs CDIO: 15.77
Cardio Diagnostics Holdings (NAS:CDIO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Cardio Diagnostics Holdings Quick Ratio Related Terms
Cardio Diagnostics Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardio Diagnostics Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardio Diagnostics Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Cardio Diagnostics Holdings's Quick Ratio falls into.
Cardio Diagnostics Holdings Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardio Diagnostics Holdings (CDIO) has a Quick Ratio of 15.77 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cardio Diagnostics Holdings and its competitors. This is 75% above median its historical median of 9.00. Over the past decade, Cardio Diagnostics Holdings' Quick Ratio has ranged from 0.64 to 23.65. According to the industry distribution chart, Cardio Diagnostics Holdings ranks #169 out of 1411 companies in the Biotechnology industry, placing it in the top 12%.
Is Cardio Diagnostics Holdings' Quick Ratio too high?
Cardio Diagnostics Holdings' current Quick Ratio of 15.77 is 75% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 23.65. The Biotechnology industry median Quick Ratio is 3.57. Cardio Diagnostics Holdings' value of 15.77 is 341.7% above this industry median. Based on the distribution chart, Cardio Diagnostics Holdings ranks #169 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cardio Diagnostics Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' Quick Ratio compare to ERNA and LABT?
According to the Biotechnology industry distribution chart, Cardio Diagnostics Holdings ranks #169 out of 1411 companies for Quick Ratio. This places Cardio Diagnostics Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.57. Cardio Diagnostics Holdings' value of 15.77 is 341.7% above this benchmark. Historically, Cardio Diagnostics Holdings' own Quick Ratio has ranged from 0.64 to 23.65 over the past decade. While the company's 10-year median is 9.00 vs. the industry median of 3.57, Cardio Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.57, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardio Diagnostics Holdings's current Quick Ratio of 15.77 is 341.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cardio Diagnostics Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardio Diagnostics Holdings's current Quick Ratio is 15.77, which is 75% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Possible Value Trap. The stock's GF Value™ is $2.77, compared to a current price of $1.57 — trading 43.3% below its estimated fair value. The current Quick Ratio is 15.77, which is 75% above median its 10-year median of 9.00 and 341.7% above the Biotechnology industry median of 3.57. Cardio Diagnostics Holdings' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current Quick Ratio is 15.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued.
The current stock price of $1.57 is trading 43.3% below its estimated GF Value™ of $2.77.
GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.
Key valuation signals for CDIO:
Quick Ratio: 15.77 (75% above median its 10-year median of 9.00)
GF Value™: $2.77 vs. price of $1.57 (43.3% below fair value)
Industry Position: 341.7% above the Biotechnology median (#169 of 1411)
No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
49GF Score
Get the complete analysis for CDIO
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIO has been successfully added to your 
